Home > A. Molecular pathology > Targeted therapy > Therapeutical antibodies > ixekizumab
ixekizumab
Tuesday 10 May 2016
| WP |
Ixekizumab binds to interleukin 17 and blocks its action. This mechanism is similar to that of another anti-psoriasis antibody, brodalumab, which also binds to the interleukin-17 receptor.
See also
IL-17 inhibitors